Results 1 to 10 of about 280,456 (250)

Lipoprotein apheresis to treat elevated lipoprotein (a)1 [PDF]

Journal of Lipid Research, 2016
An elevated plasma concentration of lipoprotein (a) [Lp(a)] is an independent risk factor for cardiovascular disease. Life style modification and currently available drugs either fail to effectively lower plasma Lp(a) levels or do not result in clinical ...
Elisa Waldmann, Klaus G. Parhofer
doaj   +7 more sources

Why Some Patients Undergoing Lipoprotein Apheresis Therapy Develop New Cardiovascular Events? [PDF]

Journal of Cardiovascular Development and Disease, 2020
Lipoprotein apheresis (LA) is an effective tool to reduce cardiovascular events (CVEs) in high-risk patients with elevations of low density lipoprotein-cholesterol (LDL-C) and/or Lipoprotein(a) (Lp(a)).
Ulrich Julius, Solveig Kuss, Sergey Tselmin, Ulrike Schatz, Stefan R. Bornstein   +4 more
doaj   +5 more sources

Case report: lipoprotein apheresis reduces the risk of cardiovascular events and prolongs pregnancy in a woman with severely elevated lipoprotein(a), cardiovascular disease, and a high risk of preeclampsia [PDF]

Frontiers in Medicine, 2023
BackgroundPreeclampsia is a common and serious pregnancy-induced disease, with potential severe maternal and fetal complications. Recently, an increased lipoprotein (a) (Lp[a]) concentration, an important factor in cardiovascular diseases (CVDs ...
Joanna Marlȩga-Linert, Katarzyna Wartecka-Zielińska, Dariusz Wydra, Marcin Fijałkowski, Marcin Gruchała, Agnieszka Mickiewicz   +5 more
doaj   +3 more sources

Lipoprotein-apheresis reduces circulating microparticles in individuals with familial hypercholesterolemia[S] [PDF]

Journal of Lipid Research, 2014
Lipoprotein-apheresis (apheresis) removes LDL-cholesterol in patients with severe dyslipidemia. However, reduction is transient, indicating that the long-term cardiovascular benefits of apheresis may not solely be due to LDL removal. Microparticles (MPs)
Katherine D. Connolly, Gareth R. Willis, Dev B.N. Datta, Elizabeth A. Ellins, Kristin Ladell, David A. Price, Irina A. Guschina, D. Aled Rees, Philip E. James   +8 more
doaj   +4 more sources

Current Role of Lipoprotein Apheresis. [PDF]

Curr Atheroscler Rep, 2019
Lipoprotein apheresis is a very efficient but time-consuming and expensive method of lowering levels of low-density lipoprotein cholesterol, lipoprotein(a)) and other apoB containing lipoproteins, including triglyceride-rich lipoproteins. First introduced almost 45 years ago, it has long been a therapy of "last resort" for dyslipidaemias that cannot ...
Thompson G, Parhofer KG.
europepmc   +7 more sources

Familial Hypercholesterolemia and Lipoprotein Apheresis. [PDF]

J Atheroscler Thromb, 2019
Lipoprotein apheresis has been developed as the treatment for refractory familial hypercholesterolemia (FH) to remove low-density lipoprotein (LDL), which is the main pathogenic factor. Currently, three procedures are available in Japan, including the plasma exchange, double-membrane filtration, and selective LDL adsorption.
Makino H, Koezuka R, Tamanaha T, Ogura M, Matsuki K, Hosoda K, Harada-Shiba M.   +6 more
europepmc   +5 more sources

Lipoprotein apheresis efficacy and challenges: single center experience [PDF]

Hematology, Transfusion and Cell Therapy, 2022
Introduction: Lipoprotein apheresis (LA) is an extracorporeal therapy which removes apolipoprotein B-containing particles from the circulation. We evaluated techniques and efficiency of lipoprotein apheresis procedures applied to patients with familial ...
Zehra Narlı Özdemir, Uğur Şahin, Yasin Yıldırım, Cansın Tulunay Kaya, Osman İlhan   +4 more
doaj   +2 more sources

Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): a case report [PDF]

Journal of Medical Case Reports, 2009
Introduction Lipoprotein glomerulopathy is a glomerulonephritis which was described for the first time by Saito in 1989 and is currently acknowledged as a separate nosological entity.
Rivasi Paolo, Romano Nicola, Magistroni Riccardo, Leonelli Marco, Furci Luciana, Russi Gianpaolo, Albertazzi Alberto   +6 more
doaj   +3 more sources

Changing from lipoprotein apheresis to evolocumab treatment lowers circulating levels of arachidonic acid and oxylipins [PDF]

Atherosclerosis Plus
Background and aims: Previous studies have shown that lipoprotein apheresis can modify the plasma lipidome and pro-inflammatory and pro-thrombotic lipid mediators.
Chaoxuan Wang, Anne Kaufmann, Nadja Kampschulte, Ulf Elbelt, Ursula Kassner, Elisabeth Steinhagen-Thiessen, Anne Pietzner, Christoph Schmöcker, Dev Datta, Tiziana Sanpietro, Nils Helge Schebb, Karsten-H. Weylandt, Nadine Rohwer   +12 more
doaj   +2 more sources

Systematic Review of Low‐Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundApheresis is an important treatment for reducing low‐density lipoprotein cholesterol (LDL‐C) in patients with familial hypercholesterolemia (FH). We systematically reviewed the current literature surrounding LDL‐C apheresis for FH.
Anthony Wang, Akshara Richhariya, Shravanthi R. Gandra, Brian Calimlim, Lisa Kim, Ruben G. W. Quek, Robert J. Nordyke, Peter P. Toth   +7 more
doaj   +2 more sources